These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32929175)

  • 41. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally.
    Kassim AA; DeBaun MR
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):532-541. PubMed ID: 38066894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.
    Kurita N; Sakamoto T; Kato T; Kusakabe M; Yokoyama Y; Nishikii H; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Ann Hematol; 2021 May; 100(5):1295-1301. PubMed ID: 33580280
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
    Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
    Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors.
    George B; Pn N; Devasia AJ; Kulkarni U; Korula A; Lakshmi KM; Abraham A; Srivastava A; Mathews V
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):494-500. PubMed ID: 29100905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.
    Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Mordini N; Berisso G; Bregante S; Frassoni F; Sessarego M; Fugazza G; Di Stefano F; Pitto A; Bacigalupo A
    Br J Haematol; 2000 Jun; 109(4):716-21. PubMed ID: 10929020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
    Montoro J; Piñana JL; Hernández-Boluda JC; Hernani R; Lorenzo I; Pérez A; Guerreiro M; Balaguer-Rosello A; Sanz GF; Carretero C; Albert E; Navarro D; Sanz MA; Solano C; Sanz J
    Bone Marrow Transplant; 2020 Nov; 55(11):2147-2159. PubMed ID: 32371901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis.
    Ali N; Butt A; Altaf B; Adil SN; Shaikh MU
    Transplant Proc; 2021; 53(1):386-390. PubMed ID: 32773285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
    Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
    J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia.
    Salas MQ; Prem S; Atenafu EG; Law AD; Lam W; Al-Shaibani Z; Loach D; Kim DDH; Michelis FV; Lipton JH; Kumar R; Mattsson J; Viswabandya A
    Eur J Haematol; 2019 Nov; 103(5):510-518. PubMed ID: 31449699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ
    Balashov D; Laberko A; Shcherbina A; Trakhtman P; Abramov D; Gutovskaya E; Kozlovskaya S; Shelikhova L; Novichkova G; Maschan M; Rumiantsev A; Maschan A
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1432-1440. PubMed ID: 29550630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Haploidentical stem cell transplantation for patients with sickle cell disease: current status.
    Pawlowska AB; Sun V; Rosenthal J
    Transfus Apher Sci; 2022 Oct; 61(5):103534. PubMed ID: 36089470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.
    Bazarbachi A; Boumendil A; Finel H; Castagna L; Dominietto A; Blaise D; Diez-Martin JL; Tischer J; Gülbas Z; Wallet HL; Corral LL; Mohty M; Koc Y; Yakoub-Agha I; Schmid C; El Cheikh J; Arat M; Forcade E; Dreger P; Rocha V; García GG; Chalandon Y; Ferra C; Orvain C; Robinson S; Montoto S; Sureda A
    Br J Haematol; 2020 Mar; 188(5):745-756. PubMed ID: 31498883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.